Document Detail

Can newer therapies delay the progression of type 2 diabetes mellitus?
MedLine Citation:
PMID:  18753109     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To review the multifactorial and progressive nature of type 2 diabetes mellitus (T2DM), the consequences of its progression, and the potential of traditional and newer therapies to delay the progression of this disease. METHODS: The relevant literature is reviewed, and the mechanisms of action of novel agents for treatment of T2DM are discussed. RESULTS: The global prevalence of diabetes has been increasing in recent decades, reaching near-epidemic proportions, and is projected to more than double by 2030. More than 90% of cases of diabetes in most countries consist of T2DM, but many individuals remain undiagnosed or are diagnosed only after their disease has progressed considerably. Inadequate glycemic control in a majority of patients with T2DM is due to the progressive nature of the disease, delay in initiating pharmacotherapy, and failure to intensify treatment more quickly in patients who do not achieve glycemic targets. Traditional oral therapies are usually effective at lowering hyperglycemia initially but do not prevent disease progression; thus, many patients ultimately require insulin. Furthermore, because most antidiabetic therapies are associated with weight gain or risk of hypoglycemia (or both), patients may not adhere to treatment recommendations. CONCLUSION: A new therapeutic approach focuses on the use of the incretin hormone glucagon-like peptide-1. Analogues of this hormone delay the progression of beta-cell dysfunction and promote beta-cell regeneration in animal models. In clinical trials, they have been shown to improve glycemic control by increasing glucose-stimulated insulin secretion and suppressing glucagon secretion. At high concentrations, they also slow gastric emptying and increase satiety, which often promotes weight loss. Another approach is to inhibit the enzyme dipeptidyl-peptidase 4, which rapidly inactivates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thereby increasing endogenous incretin levels.
Edward S Horton
Related Documents :
15877889 - Impact of inulin and oligofructose on gastrointestinal peptides.
9628239 - Overnight glp-1 normalizes fasting but not daytime plasma glucose levels in niddm patie...
19477229 - Effect of intracerebroventricular infusion of insulin on glucose-dependent insulinotrop...
19571229 - Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-respo...
12635849 - Cyclic amp production and insulin releasing activity of synthetic fragment peptides of ...
7507399 - Effect of chronic ddc treatment on lhrh and substance p amidation processes in the rat.
16822679 - Resistin and adiponectin levels in subjects with coronary artery disease and type 2 dia...
22187639 - Healthy eating index and alternate healthy eating index among haitian americans and afr...
15251769 - Effect of premixed nph and regular insulin on glucose control and health-related qualit...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists     Volume:  14     ISSN:  1934-2403     ISO Abbreviation:  Endocr Pract     Publication Date:    2008 Jul-Aug
Date Detail:
Created Date:  2008-08-28     Completed Date:  2009-01-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607439     Medline TA:  Endocr Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  625-38     Citation Subset:  IM    
Joslin Diabetes Center, Boston, MA 02215, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diabetes Mellitus, Type 2 / drug therapy*,  metabolism,  pathology
Disease Progression
Glucagon-Like Peptide 1 / administration & dosage,  adverse effects,  therapeutic use*
Hypoglycemic Agents / administration & dosage,  adverse effects,  therapeutic use*
Insulin / administration & dosage,  adverse effects,  therapeutic use
Reg. No./Substance:
0/Hypoglycemic Agents; 11061-68-0/Insulin; 89750-14-1/Glucagon-Like Peptide 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.
Next Document:  Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective.